In an open-label phase 2 trial, patients with non-small-cell lung cancer received neoadjuvant anti-PD-1 with or without anti-LAG-3, showing that curative intent surgery after combined blockade of PD-1 and LAG-3 is feasible, and leads to preliminary clinical responses. The gene discussed is LAG3; the disease is non-small cell lung carcinoma.